ad image

Company Info

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals

Drug Discovery & Development

Overview

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. 
Mallinckrodt Pharmaceuticals
Contributions
11 Contributions1 / 1
Mallinckrodt Pharmaceuticals
M&A

Mallinckrodt and Silence Therapeutics Announce Collaboration to Develop And Commercialize RNAi Therapeutics for Complement-Mediated Diseases

Mallinckrodt Pharmaceuticals

PR-M07-19-NI-059Jul 23, 2019
Mallinckrodt Pharmaceuticals
Generics

Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders

Mallinckrodt Pharmaceuticals

PR-M05-19-NI-087May 31, 2019
Mallinckrodt Pharmaceuticals
Research

Mallinckrodt Presents Data on Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting

Mallinckrodt Pharmaceuticals

PR-M03-19-NI-013Mar 06, 2019
Mallinckrodt Pharmaceuticals
Rheumatology

Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 ACR/ARHP Annual Meeting

Mallinckrodt Pharmaceuticals

PR-M10-18-NI-092Oct 26, 2018
Mallinckrodt Pharmaceuticals
Skin Graft

Mallinckrodt's Stratatech Company Awarded $26 Million in Additional BARDA Funding for Pediatric Studies of StrataGraft® Skin Tissue in Thermal Burns

Mallinckrodt Pharmaceuticals

PR-M10-18-NI-063Oct 18, 2018
Mallinckrodt Pharmaceuticals
Collaborative Research Partnership

Mallinckrodt Forms Collaborative Research Partnership with Washington University in St. Louis

Mallinckrodt Pharmaceuticals

PR-M08-18-NI-056Aug 14, 2018
Mallinckrodt Pharmaceuticals
Clinical Data

Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

Mallinckrodt Pharmaceuticals

PR-M07-18-NI-009Jul 03, 2018
Mallinckrodt Pharmaceuticals
Scientific Advisory Council

Mallinckrodt Launches Scientific Advisory Council

Mallinckrodt Pharmaceuticals

PR-M06-18-NI-081Jun 25, 2018
Mallinckrodt Pharmaceuticals
FDA Acceptance

Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing

Mallinckrodt Pharmaceuticals

PR-M02-18-NI-106Feb 28, 2018
Mallinckrodt Pharmaceuticals
Clinical Trials

Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue

Mallinckrodt Pharmaceuticals

PR-M02-18-NI-74Feb 20, 2018
Mallinckrodt Pharmaceuticals
Acquisition

Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.

Mallinckrodt Pharmaceuticals

PR-M02-18-NI-62Feb 16, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0